IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.
Lih En HongMihir D WechalekarMonika KutynaAnnabelle G SmallKelly LimChloe A L Thompson-PeachJoule J LiRakchha ChhetriHamish S ScottAnna L BrownChristopher N HahnDavid T YeungSalvia SajidNirmal RobinsonRanjeny ThomasSusan BranfordRichard J J D'AndreaSaumya E E SamaraweeraMirinal S PatnaikSusanna M ProudmanDaniel ThomasChung Hoow KokMithun Vinod ShahDevendra K HiwasePublished in: Blood (2024)
High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.